Author:
Russo Alfonso,Örzsik Balázs,Yalin Nefize,Simpson Ivor,Nwaubani Prince,Pinna Antonello,De Marco Riccardo,Sharp Harriet,Kartar Amy,Singh Nisha,Blockley Nicholas,Stone Alan John Luke,Turkheimer Federico E.,Young Allan H.,Cercignani Mara,Zelaya Fernando,Asllani Iris,Colasanti Alessandro
Reference70 articles.
1. Methylene blue in the treatment of neuropsychiatric disorders;Alda;CNS Drugs,2019
2. Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study;Alda;Br. J. Psychiatry,2017
3. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia;Alsop;Magn. Reson. Med.,2015
4. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder;Andreazza;J. Psychiatry Neurosci.,2009
5. Andreazza, A.C., Shao, L., Wang, J.F., Young, L.T., 2010. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder.[Erratum appears in Arch. Gen. Psychiatry 2010 Dec;67(12):1254]. Arch Gen Psychiatry 67, 360–368.